Hitachi Chemical Advanced Therapeutics Solutions Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Hitachi Chemical Advanced Therapeutics Solutions's estimated annual revenue is currently $47.6M per year.
- Hitachi Chemical Advanced Therapeutics Solutions's estimated revenue per employee is $155,000
- Hitachi Chemical Advanced Therapeutics Solutions has 307 Employees.
- Hitachi Chemical Advanced Therapeutics Solutions grew their employee count by 13% last year.
- Hitachi Chemical Advanced Therapeutics Solutions currently has 52 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Hitachi Chemical Advanced Therapeutics Solutions?
Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), is a wholly owned subsidiary of Hitachi Chemical Company, Ltd. representing its Regenerative Medicine Business Sector. Its vision is a world in which transformative cell-based therapeutics are accessible to all, and its mission is to provide its clients with high-quality, scalable, innovative, reliable and cost-efficient manufacturing platforms and services to advance commercialization of cellular therapies. HCATS offers PCT, a cell therapy manufacturing and development service platform, leveraging nearly two decades of experience exclusively focused on the cell therapy industry. The PCT service platform includes contract development and manufacturing organization (CDMO) services, at current Good Manufacturing Practices (cGMP) standards, including clinical and commercial manufacturing, manufacturing development, and technology development. HCATS operates cGMP manufacturing facilities in the U.S. in Allendale, New Jersey (headquarters) and Mountain View, California. A facility in Yokohama, Japan is now under construction and another U.S. facility is planned for Allendale. European operations will begin in 2018. All facilities operate on our global, harmonized PCT service platform. In the future, HCATS will expand the scope of its services to offer other services or products distinct from those currently under PCT, under separate platforms. Our Resume 30,000+ products manufactured 18,000+ products stored 14,000+ product deliveries made 6,000+ patients treated with our products 100+ Clients with proven results 50+ regulatory filings in US & EU 30+ technology transfers performed Proven successful regulatory track record Our Commitment Unparalleled customer service Client-driven project teams No IP claims to the products we develop for Clients Dedicated to Client success Our Capacity Full-scale cGMP/GLP operations in New Jersey and California, with Yokohama, Japan facility beginning client manufacturing in April 2018 Thousands of square feet of Class 10,000 clean rooms, and full QA/QC support R&D laboratories, GTP processing, and cryostorage facilities Bicoastal distribution and delivery State-of-the-art analytical, cell processing and manufacturing equipment Our Expertise 25+ different types of cells and tissues Cell culture and expansion technologies Cell engineering technologies Automation, innovation and engineering Cell collection, isolation, and purification Cellular product formulation and cryopreservation Biological assays and analytical methods Storage, shipping, and delivery procedures Follow us on Twitter @PCTcelltherapykeywords:N/A
Number of Employees
Employee Growth %
Hitachi Chemical Advanced Therapeutics Solutions News
... Therapy World Conference, HemaCare partnered with Hitachi Chemical Advanced Therapeutics Solutions (HCATS) on a presentation titled, ...
Hitachi Chemical Advanced Therapeutics Solutions Signs Three-Year Agreement with GSK to Provide Clinical Manufacturing for T Cell ...
ALLENDALE, N.J.--(BUSINESS WIRE)--Hitachi Chemical Advanced Therapeutics Solutions, LLC announces an agreement by which apceth ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|